Commonwealth Equity Services
ADCT icon

Commonwealth Equity Services’s ADC Therapeutics ADCT Stock Holding History

Commonwealth Equity Services’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Sell
15,519
-2,250
-13% -$6.56K ﹤0.01% 4377
2026
Q1 		$66.6K Sell
17,769
-40
-0.2% -$158 ﹤0.01% 4177
2025
Q4 		$62.9K Sell
17,809
-5,001
-22% -$20.3K ﹤0.01% 4160
2025
Q3 		$91K Sell
22,810
-1,767
-7% -$5.57K ﹤0.01% 4101
2025
Q2 		$66K Sell
24,577
-14,734
-37% -$31K ﹤0.01% 4129
2025
Q1 		$55K Sell
39,311
-300
-0.8% -$510 ﹤0.01% 4055
2024
Q4 		$79K Sell
39,611
-802
-2% -$2.1K ﹤0.01% 3938
2024
Q3 		$127K Buy
40,413
+7,813
+24% +$24.6K ﹤0.01% 3824
2024
Q2 		$103K Buy
32,600
+13,783
+73% +$54.8K ﹤0.01% 3806
2024
Q1 		$84K Sell
18,817
-1,035
-5% -$3.82K ﹤0.01% 3827
2023
Q4 		$33K Buy
+19,852
New +$18.3K ﹤0.01% 3790
2023
Q2 		– Sell
-10,093
Closed -$19K – 3832
2023
Q1 		$19K Buy
+10,093
New +$37.2K ﹤0.01% 3673

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Commonwealth Equity Services's ADCT Position: Q2 2026 in Review

Commonwealth Equity Services reduced its ADC Therapeutics (ADCT) stake by 13% in Q2 2026, selling an estimated $6.56K and leaving 15,519 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4377.

Commonwealth Equity Services first reported a position in ADCT in Q1 2023 and has held it in 12 quarters since. The position peaked at $127K in Q3 2024. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Commonwealth Equity Services held 15,519 shares of ADC Therapeutics worth $16.6K as of Q2 2026.
  • Commonwealth Equity Services sold 2,250 ADC Therapeutics shares in Q2 2026, an estimated $6.56K.
  • ADC Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4377 holding.
  • Commonwealth Equity Services first reported a position in ADC Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Commonwealth Equity Services's ADC Therapeutics position peaked at $127K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.